Antisense therapy for cancer
نویسندگان
چکیده
منابع مشابه
Clinical studies of antisense therapy in cancer.
The ability to target and inhibit individual gene expression with antisense oligonucleotides has shown promising activity in preclinical cancer models. Recent clinical studies have tested antisense compounds directed against seven cancer related genes including p53, bcl-2, c-raf, H-ras, protein kinase C-alpha, and protein kinase A. Class specific effects of the phosphorothioate backbone common ...
متن کاملCombination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
PURPOSE A wide variety of tumors depend on the dysregulation of Bcl-2 family proteins for survival. The resulting apoptotic block can often provide a mechanism for resistance to anticancer treatments, such as chemotherapy and radiation. This current study evaluates the efficacy of combining systemically delivered Bcl-2 phosphorothioate antisense (Bcl-2 ASO) and radiation for nasopharyngeal canc...
متن کاملAntisense Therapy in Neurology
Antisense therapy is an approach to fighting diseases using short DNA-like molecules called antisense oligonucleotides. Recently, antisense therapy has emerged as an exciting and promising strategy for the treatment of various neurodegenerative and neuromuscular disorders. Previous and ongoing pre-clinical and clinical trials have provided encouraging early results. Spinal muscular atrophy (SMA...
متن کاملAntisense Gene Silencing: Therapy for Neurodegenerative Disorders?
Since the first reports that double-stranded RNAs can efficiently silence gene expression in C. elegans, the technology of RNA interference (RNAi) has been intensively exploited as an experimental tool to study gene function. With the subsequent discovery that RNAi could also be applied to mammalian cells, the technology of RNAi expanded from being a valuable experimental tool to being an appli...
متن کاملMaking sense of antisense therapy for hypertension.
ed in the regulation of vascular tone. Whilst pharmacological antagonism of ‚-adrenoceptors is still part of the mainstay treatment for hypertension, ·adrenoreceptor blockade is rarely used as a front line therapy. In the ALLHAT study peripheral ·-blockade in high risk hypertensive patients led to a 25% increase in cardiovascular events and doubled the likelihood of hospital admissions. Althoug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2003
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)00011-9